Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes Dedicated Actinium-225 Production Facility

0

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Tag(s): Incoming orders

Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes Dedicated Actinium-225 Production Facility
11.10.2022 / 14:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Berlin, Germany and BELOIT, Wis., October 11, 2022 – Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist in radiopharmaceutical plant engineering and a wholly owned subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced an agreement to purchase hot cells and related equipment for actinium-225 (Ac -225) production site. Hot cells are shielded enclosures specially designed to allow the safe handling of radioactive materials. The multi-million dollar equipment will be used by NorthStar in Beloit, Wisconsin to produce commercial quantities of nec Ac-225. Ac-225 is an emerging medical radioisotope that can be used in the treatment of cancer. The manufacturing process for these advanced radiopharmaceuticals requires innovative solutions and equipment to enable large-scale routine commercial production of Ac-225.

“This agreement underlines our long-standing and extensive know-how in the construction of special tailor-made installations, both in terms of its scale and with regard to the technological requirements”, explained Felix Husmann, managing director of the subsidiary. of Eckert & Ziegler, Isotope Technologies Dresden GmbH. . “We are proud that a leading radiopharmaceutical company like NorthStar trusts our process development expertise.”

“NorthStar is confident that we will be the first commercial-scale supplier of nec Ac-225 using our environmentally preferable, non-uranium-based electron accelerator technology,” said Stephen Merrick, President and CEO of NorthStar Medical Radioisotopes. preliminary stages of this project, we have had the full support of the technology team at ITD, which we consider to be the industry’s leading specialist in turnkey facilities for radiochemical and radiopharmaceutical processes, and we anticipate that their technical solutions will enable us to make a significant contribution to the global Ac-225 supply market in the future.”

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG, with more than 900 employees, is a leading specialist for isotope-related components in nuclear medicine and radiotherapy. The company offers a wide range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in Deutsche Börse’s SDAX index. Contribute to saving lives.

About Isotope Technologies Dresden
Isotope Technologies Dresden GmbH (ITD) is a subsidiary of Eckert & Ziegler AG and one of the leading international specialists in the development, design and manufacture of hot cells for production, materials testing, research and development and other applications in the radiopharmaceutical and industrial sectors. ITD has many years of experience in the development, manufacture and installation of special customer-specific equipment.

About NorthStar Medical Radioisotopes
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radioisotopes and radiopharmaceuticals. The company’s proprietary advanced technology and proven management team have propelled it to the forefront of medical radioisotope production in the United States as the only domestic producer of diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the standard of care in diagnostic imaging for assessing the extent and severity of heart disease and cancer. NorthStar’s unique Mo-99 production process is uranium-free and environmentally friendly. NorthStar is expanding its position as an industry leader in the emerging field of therapeutic radioisotopes, which are used in targeted radiopharmaceutical therapy to treat cancer, respiratory diseases and other illnesses. Using groundbreaking, environmentally friendly electron accelerator technology, NorthStar is poised to become the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu -67). NorthStar also collaborates with other companies in the development of radiopharmaceuticals. For more information on NorthStar’s comprehensive radiopharmaceutical portfolio, visit: www.northstarnm.com.

Contact:
Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
[email protected] / [email protected]
Such. : +49 (0) 30 / 94 10 84-138; www.ezag.de

NorthStar Medical Radioisotopes, LLC
Company :
Lisa Holst
Vice President Sales and Marketing
678-471-9027
[email protected]

Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
[email protected]

Media:
Priscilla Harlan
781-799-7917
[email protected]


11.10.2022 CET/CEST Broadcast of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

EQS distribution services include regulatory announcements, financial/corporate news and press releases.
Archives on www.eqs-news.com


Share.

Comments are closed.